D
BioVaxys Technology Corp.
BIOV
CNSX
D
Sell
1/22/2025Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E+ on 1/22/2025 due to an increase in the volatility index.
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E+ on 1/22/2025 due to an increase in the volatility index.
E
Sell
1/7/2025Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to E+ from D- on 1/7/2025 due to a decline in the volatility index and growth index.
BioVaxys Technology Corp. (BIOV) was downgraded to E+ from D- on 1/7/2025 due to a decline in the volatility index and growth index.
D
Sell
10/9/2024Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E+ on 10/9/2024 due to an increase in the volatility index, growth index and solvency index. Debt to equity declined from -0.06 to -0.33, the quick ratio increased from 0.11 to 0.33, and operating cash flow increased 6.52% from -$322 to -$301.
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E+ on 10/9/2024 due to an increase in the volatility index, growth index and solvency index. Debt to equity declined from -0.06 to -0.33, the quick ratio increased from 0.11 to 0.33, and operating cash flow increased 6.52% from -$322 to -$301.
E
Sell
9/30/2024Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to E+ from D- on 9/30/2024 due to a noticeable decline in the growth index, volatility index and valuation index. Operating cash flow declined 17,988.89% from $1.8 to -$322, earnings per share declined from $0.0026 to -$0.0019, and EBIT declined 40.84% from -$254.4 to -$358.3.
BioVaxys Technology Corp. (BIOV) was downgraded to E+ from D- on 9/30/2024 due to a noticeable decline in the growth index, volatility index and valuation index. Operating cash flow declined 17,988.89% from $1.8 to -$322, earnings per share declined from $0.0026 to -$0.0019, and EBIT declined 40.84% from -$254.4 to -$358.3.
D
Sell
1/8/2024Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E+ on 1/8/2024 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 96.61% from -$525.5 to -$17.8, EBIT increased 34.77% from -$392.3 to -$255.9, and earnings per share increased from -$0.0084 to -$0.008.
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E+ on 1/8/2024 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 96.61% from -$525.5 to -$17.8, EBIT increased 34.77% from -$392.3 to -$255.9, and earnings per share increased from -$0.0084 to -$0.008.
E
Sell
3/16/2023Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to E+ from D- on 3/16/2023 due to a decline in the total return index and volatility index.
BioVaxys Technology Corp. (BIOV) was downgraded to E+ from D- on 3/16/2023 due to a decline in the total return index and volatility index.
D
Sell
3/8/2023Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 3/8/2023 due to a significant decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0072 to -$0.0606, operating cash flow declined 166.72% from -$58.9 to -$157.1, and EBIT declined 1.44% from -$650.6 to -$660.
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 3/8/2023 due to a significant decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0072 to -$0.0606, operating cash flow declined 166.72% from -$58.9 to -$157.1, and EBIT declined 1.44% from -$650.6 to -$660.
D
Sell
2/23/2023Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index.
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
10/3/2022Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 10/3/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 91.17% from -$666.7 to -$58.9, EBIT increased 16.94% from -$783.3 to -$650.6, and earnings per share increased from -$0.0086 to -$0.0072.
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 10/3/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 91.17% from -$666.7 to -$58.9, EBIT increased 16.94% from -$783.3 to -$650.6, and earnings per share increased from -$0.0086 to -$0.0072.
D
Sell
9/30/2022Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 9/30/2022 due to a decline in the volatility index.
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 9/30/2022 due to a decline in the volatility index.
D
Sell
9/8/2022Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 9/8/2022 due to a major increase in the growth index. Earnings per share increased from -$0.0104 to -$0.0086, and EBIT increased 9.47% from -$865.2 to -$783.3.
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 9/8/2022 due to a major increase in the growth index. Earnings per share increased from -$0.0104 to -$0.0086, and EBIT increased 9.47% from -$865.2 to -$783.3.
D
Sell
3/4/2022Downgrade
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 3/4/2022 due to a major decline in the growth index, efficiency index and total return index. EBIT declined 194.26% from -$644.1 to -$1.9M, net income declined 172.25% from -$736.3 to -$2M, and earnings per share declined from -$0.0089 to -$0.0219.
BioVaxys Technology Corp. (BIOV) was downgraded to D- from D on 3/4/2022 due to a major decline in the growth index, efficiency index and total return index. EBIT declined 194.26% from -$644.1 to -$1.9M, net income declined 172.25% from -$736.3 to -$2M, and earnings per share declined from -$0.0089 to -$0.0219.
D
Sell
11/3/2021Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index, growth index and volatility index. EBIT increased 40.58% from -$1.08M to -$644.1, and earnings per share increased from -$0.0146 to -$0.0089.
BioVaxys Technology Corp. (BIOV) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index, growth index and volatility index. EBIT increased 40.58% from -$1.08M to -$644.1, and earnings per share increased from -$0.0146 to -$0.0089.
D
Sell
7/1/2021Upgraded
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E on 7/1/2021 due to an increase in the total return index.
BioVaxys Technology Corp. (BIOV) was upgraded to D- from E on 7/1/2021 due to an increase in the total return index.
E
Sell
6/30/2021None
BioVaxys Technology Corp. (BIOV) was downgraded to E from U on 06/30/2021.
BioVaxys Technology Corp. (BIOV) was downgraded to E from U on 06/30/2021.
